{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:03:04Z","timestamp":1789275784660,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012818","name":"Community of Madrid","doi-asserted-by":"publisher","award":["PEJ-2023-AI\/SAL-GL-27249"],"award-info":[{"award-number":["PEJ-2023-AI\/SAL-GL-27249"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Government of Catalonia","doi-asserted-by":"publisher","award":["2021 SGR 00776"],"award-info":[{"award-number":["2021 SGR 00776"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012006","name":"Conchita Rabago Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI24\/00192"],"award-info":[{"award-number":["PI24\/00192"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["CB16\/12\/00481"],"award-info":[{"award-number":["CB16\/12\/00481"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI21\/00142"],"award-info":[{"award-number":["PI21\/00142"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI24\/00160"],"award-info":[{"award-number":["PI24\/00160"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI21\/00002"],"award-info":[{"award-number":["PI21\/00002"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["FI22\/00324"],"award-info":[{"award-number":["FI22\/00324"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.neo.2026.101318","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T03:08:07Z","timestamp":1779160087000},"page":"101318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer"],"prefix":"10.1016","volume":"78","author":[{"given":"Melani","family":"Luque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Morales-Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sanz-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Argui\u00f1ano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamileth","family":"Rangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7838-967X","authenticated-orcid":false,"given":"Natalia","family":"Ram\u00edrez-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7014-7188","authenticated-orcid":false,"given":"Mengjuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Albanell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8094-4076","authenticated-orcid":false,"given":"Juan","family":"Madoz-G\u00farpide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2026.101318_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.neo.2026.101318_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.neo.2026.101318_bib0003","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/annonc\/12.suppl_1.S35","article-title":"Mechanism of action of anti-HER2 monoclonal antibodies","volume":"12","author":"Baselga","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neo.2026.101318_bib0004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of Neoadjuvant Pertuzumab and Trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.neo.2026.101318_bib0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus Trastuzumab plus Docetaxel for metastatic Breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2026.101318_bib0006","first-page":"9","article-title":"Different pathological complete response rates according to PAM50 subtype in HER2+ breast cancer patients treated with neoadjuvant Pertuzumab\/Trastuzumab vs. Trastuzumab plus standard chemotherapy: an analysis of real-world data","author":"D\u00edaz-Redondo","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neo.2026.101318_bib0007","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2026.101318_bib0008","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2026.101318_bib0009","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature03096","article-title":"Stromal fibroblasts in cancer initiation and progression","volume":"432","author":"Bhowmick","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.neo.2026.101318_bib0010","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrc1877","article-title":"Fibroblasts in cancer","volume":"6","author":"Kalluri","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2026.101318_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201700167","article-title":"Cancer associated fibroblasts: the architects of stroma remodeling","volume":"18","author":"Santi","year":"2018","journal-title":"Proteomics"},{"key":"10.1016\/j.neo.2026.101318_bib0012","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s12094-022-03027-y","article-title":"Cancer secretome: finding out hidden messages in extracellular secretions","volume":"25","author":"Padgaonkar","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.neo.2026.101318_bib0013","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1039\/C4MB00710G","article-title":"Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast Cancer cells","volume":"11","author":"Mao","year":"2015","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.neo.2026.101318_bib0014","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1016\/j.celrep.2018.12.015","article-title":"Dissecting effects of anti-cancer drugs and cancer-associated fibroblasts by on-chip reconstitution of immunocompetent tumor microenvironments","volume":"25","author":"Nguyen","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.neo.2026.101318_bib0015","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1158\/1078-0432.CCR-19-0353","article-title":"Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation","volume":"26","author":"Fern\u00e1ndez-Nogueira","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101318_bib0016","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1158\/1078-0432.CCR-16-2287","article-title":"HER2-Overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2","volume":"23","author":"Hanker","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101318_bib0017","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/ijc.32859","article-title":"Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer","volume":"147","author":"Sonnenblick","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.neo.2026.101318_bib0018","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1158\/1078-0432.CCR-20-2915","article-title":"Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on Trastuzumab and Pertuzumab activity in HER2-positive breast cancer","volume":"27","author":"Guardia","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101318_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413297","article-title":"Targeted therapy modulates the secretome of cancer-associated fibroblasts to induce resistance in HER2-positive breast cancer","volume":"22","author":"Luque","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neo.2026.101318_bib0020","first-page":"9","article-title":"The calcium binding protein S100A11 and its roles in diseases","author":"Zhang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neo.2026.101318_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2015.05.002","article-title":"Conditioning solid tumor microenvironment through inflammatory chemokines and S100 Family proteins","volume":"365","author":"Nasser","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.neo.2026.101318_bib0022","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2026.101318_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41389-017-0017-3","article-title":"Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma","volume":"7","author":"Sato","year":"2018","journal-title":"Oncogenesis"},{"key":"10.1016\/j.neo.2026.101318_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100751","article-title":"Emerging targets for cancer treatment: S100A9\/RAGE","volume":"8","author":"Valiente","year":"2023","journal-title":"ESMo Open."},{"key":"10.1016\/j.neo.2026.101318_bib0025","first-page":"2661","article-title":"Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines","volume":"6","author":"Zazo","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.neo.2026.101318_bib0026","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","article-title":"Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment","volume":"16","author":"Pegram","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2026.101318_bib0027","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00280-013-2279-6","article-title":"Exposure-response analysis of Pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters","volume":"72","author":"Garg","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.neo.2026.101318_bib0028","doi-asserted-by":"crossref","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","article-title":"Insulin-like growth factor-I receptor\/Human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells","volume":"65","author":"Nahta","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2026.101318_bib0029","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/1078-0432.CCR-12-2024","article-title":"Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function","volume":"19","author":"Garrett","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101318_bib0030","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.neo.2026.101318_bib0031","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12967-015-0633-7","article-title":"Activation of MET pathway predicts poor outcome to Cetuximab in patients with recurrent or metastatic Head and Neck cancer","volume":"13","author":"Madoz-G\u00farpide","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.neo.2026.101318_bib0032","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth edition of the AJCC cancer staging manual: breast Cancer","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.neo.2026.101318_bib0033","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1040-8428(99)00034-7","article-title":"Pathological prognostic factors in breast cancer","volume":"31","author":"Elston","year":"1999","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.neo.2026.101318_bib0034","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for Human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.neo.2026.101318_bib0035","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival","volume":"12","author":"Ogston","year":"2003","journal-title":"Breast"},{"key":"10.1016\/j.neo.2026.101318_bib0036","series-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2016"},{"key":"10.1016\/j.neo.2026.101318_bib0037","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-006-9242-8","article-title":"Statistics subcommittee of NCI-EORTC Working Group on cancer diagnostics REporting recommendations for tumor MARKer prognostic studies (REMARK)","volume":"100","author":"McShane","year":"2006","journal-title":"Breast. Cancer Res. Treat."},{"key":"10.1016\/j.neo.2026.101318_bib0038","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12943-019-0994-2","article-title":"Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance","volume":"18","author":"Fiori","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.neo.2026.101318_bib0039","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2026.101318_bib0040","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3390\/cancers14061519","article-title":"B\u00eate Noire of chemotherapy and targeted therapy: cAF-mediated resistance","volume":"14","author":"De","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.neo.2026.101318_bib0041","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13046-022-02524-w","article-title":"The importance of being CAFs (in Cancer Resistance to Targeted Therapies)","volume":"41","author":"Rizzolio","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101318_bib0042","article-title":"S100A11 Promotes glioma cell proliferation and predicts grade-correlated unfavorable prognosis","volume":"20","author":"Wang","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.neo.2026.101318_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-022-05004-3","article-title":"S100A11 Activates the pentose phosphate pathway to induce malignant biological behaviour of pancreatic ductal adenocarcinoma","volume":"13","author":"Zeng","year":"2022","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.neo.2026.101318_bib0044","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11010-011-1026-8","article-title":"Selective expression of S100A11 in lung cancer and its role in regulating proliferation of adenocarcinomas cells","volume":"359","author":"Hao","year":"2012","journal-title":"Mol. Cell Biochem."},{"key":"10.1016\/j.neo.2026.101318_bib0045","first-page":"3385","article-title":"HGF-mediated S100A11 overexpression enhances proliferation and invasion of gastric cancer","volume":"10","author":"Koh","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.neo.2026.101318_bib0046","doi-asserted-by":"crossref","first-page":"12156","DOI":"10.18632\/oncotarget.3495","article-title":"Tudor staphylococcal nuclease driveschemoresistance of non-small cell lung carcinoma cells by regulating S100A11","volume":"6","author":"Zagryazhskaya","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2026.101318_bib0047","first-page":"12","article-title":"Novel immune-related gene-based signature characterizing an inflamed microenvironment predicts prognosis and radiotherapy efficacy in glioblastoma","author":"Ji","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.neo.2026.101318_bib0048","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/156652413804486214","article-title":"Functions of S100 proteins","volume":"13","author":"Donato","year":"2013","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.neo.2026.101318_bib0049","doi-asserted-by":"crossref","first-page":"8296","DOI":"10.4049\/jimmunol.175.12.8296","article-title":"Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products","volume":"175","author":"Cecil","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.neo.2026.101318_bib0050","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1091\/mbc.e07-07-0682","article-title":"S100A11, an dual mediator for growth regulation of Human keratinocytes","volume":"19","author":"Sakaguchi","year":"2008","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.neo.2026.101318_bib0051","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-med-041316-085215","article-title":"Targeting RAGE signaling in inflammatory disease","volume":"69","author":"Hudson","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.neo.2026.101318_bib0052","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1189\/jlb.1012519","article-title":"RAGE regulation and signaling in inflammation and beyond","volume":"94","author":"Kierdorf","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.neo.2026.101318_bib0053","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molimm.2021.09.014","article-title":"S100A11 Regulates nasal epithelial cell remodeling and inflammation in CRSwNPs via the RAGE-mediated AMPK-STAT3 pathway","volume":"140","author":"Liu","year":"2021","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.neo.2026.101318_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154815","article-title":"Differences in P38-STAT3-S100A11 signaling after the administration of Aristolochic Acid I and IVa may account for the disparity in their nephrotoxicity","volume":"114","author":"Xian","year":"2023","journal-title":"Phytomedicine"},{"issue":"3","key":"10.1016\/j.neo.2026.101318_bib0055","doi-asserted-by":"crossref","first-page":"3-P-272","DOI":"10.1254\/jpssuppl.95.0_3-P-272","article-title":"Azeliragon, a RAGE antagonist, suppresses cell survival and proliferation of Human prostate cancer-derived LNCaP cells: analysis of altered cell signaling","volume":"95","author":"Shibano","year":"2022","journal-title":"Proc. Annu. Meet JPN Pharmacol. Soc."},{"key":"10.1016\/j.neo.2026.101318_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175703","article-title":"Azeliragon inhibits PAK1 and enhances the therapeutic efficacy of AKT inhibitors in pancreatic cancer","volume":"948","author":"Kong","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neo.2026.101318_bib0057","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1158\/0008-5472.CAN-14-2161","article-title":"RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment","volume":"75","author":"Nasser","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2026.101318_bib0058","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1159\/000449326","article-title":"Increased expression of the receptor for advanced glycation end-products (RAGE) is associated with advanced breast cancer stage","volume":"39","author":"Nankali","year":"2016","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.neo.2026.101318_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-023-00564-9","article-title":"RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer","volume":"9","author":"Magna","year":"2023","journal-title":"NPJ Breast. Cancer"},{"key":"10.1016\/j.neo.2026.101318_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128444","article-title":"Design, Synthesis and anti-TNBC activity of Azeliragon triazole analogues","volume":"54","author":"Xie","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neo.2026.101318_bib0061","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12935-022-02599-7","article-title":"Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures","volume":"22","author":"Feng","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.neo.2026.101318_bib0062","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/ijms24010266","article-title":"RAGE inhibitors for targeted therapy of cancer: a comprehensive review","volume":"24","author":"Faruqui","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neo.2026.101318_bib0063","doi-asserted-by":"crossref","first-page":"88","DOI":"10.7150\/jca.78011","article-title":"S100A11: a potential carcinogen and prognostic marker that correlates with the immunosuppressive microenvironment in Pan-cancer","volume":"14","author":"Ji","year":"2023","journal-title":"J. Cancer"},{"key":"10.1016\/j.neo.2026.101318_bib0064","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2559.2005.02097.x","article-title":"Expression of S100 proteins in normal Human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers","volume":"46","author":"Cross","year":"2005","journal-title":"Histopathology"},{"key":"10.1016\/j.neo.2026.101318_bib0065","article-title":"Distinct prognostic values of S100 mRNA expression in breast cancer","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neo.2026.101318_bib0066","first-page":"1301","article-title":"Ca2+-Binding protein S100A11: a novel diagnostic marker for breast carcinoma","volume":"23","author":"Liu","year":"2010","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.neo.2026.101318_bib0067","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3892\/ijo.2013.2195","article-title":"STAT3 Activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits","volume":"44","author":"Chung","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.neo.2026.101318_bib0068","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.neo.2026.101318_bib0069","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.neo.2026.101318_bib0070","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus Trastuzumab predicts favorable survival in Human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG Study groups","volume":"29","author":"Untch","year":"2011","journal-title":"J. Clin. Oncol."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:00:09Z","timestamp":1783137609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558626000485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":70,"alternative-id":["S1476558626000485"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2026.101318","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2026.101318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101318"}}